dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Mòdol-Caballero, Guillem |
dc.contributor.author | Herrando-Grabulosa, Mireia |
dc.contributor.author | Verdés Franquesa, Sergi |
dc.contributor.author | García-Lareu, Belén |
dc.contributor.author | Hernández, Neus |
dc.contributor.author | Francos-Quijorna, Isaac |
dc.contributor.author | Bosch Merino, Assumpció |
dc.date.accessioned | 2022-05-03T12:49:05Z |
dc.date.available | 2022-05-03T12:49:05Z |
dc.date.issued | 2021-09-22 |
dc.identifier.citation | Mòdol-Caballero G, Herrando-Grabulosa M, Verdés S, García-Lareu B, Hernández N, Francos-Quijorna I, et al. Gene Therapy Overexpressing Neuregulin 1 Type I in Combination With Neuregulin 1 Type III Promotes Functional Improvement in the SOD1G93A ALS Mice. Front Neurol. 2021 Sep 22;12:693309. |
dc.identifier.issn | 1664-2295 |
dc.identifier.uri | https://hdl.handle.net/11351/7464 |
dc.description | Motoneurona; Neuregulina 1; Medul·la espinal |
dc.description.sponsorship | This work was funded by grant TV3201428-10 of Fundació La Marato-TV3, grant #20289 of AFM-Telethon, cooperative project 2015-01 from CIBERNED, PID2020-116735RB-I00 from MICINN and TERCEL (RD16/0011/0014) funds from the Instituto de Salud Carlos III of Spain. |
dc.language.iso | eng |
dc.publisher | Frontiers Media |
dc.relation.ispartofseries | Frontiers in Neurology;12 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Esclerosi lateral amiotròfica - Tractament |
dc.subject | Teràpia genètica |
dc.subject | Ratolins transgènics |
dc.subject.mesh | Amyotrophic Lateral Sclerosis |
dc.subject.mesh | /therapy |
dc.subject.mesh | Genetic Therapy |
dc.subject.mesh | Mice, Transgenic |
dc.title | Gene Therapy Overexpressing Neuregulin 1 Type I in Combination With Neuregulin 1 Type III Promotes Functional Improvement in the SOD1G93A ALS Mice |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3389/fneur.2021.693309 |
dc.subject.decs | esclerosis lateral amiotrófica |
dc.subject.decs | /terapia |
dc.subject.decs | terapia genética |
dc.subject.decs | ratones transgénicos |
dc.relation.publishversion | https://doi.org/10.3389/fneur.2021.693309 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Mòdol-Caballero G, Herrando-Grabulosa M, Hernández N, Francos-Quijorna I] Departament de Biologia Cel•lular, Fisiologia i Immunologia, Institut de Neurociències, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain. [Verdés S] Departament de Bioquímica i Biologia Molecular, Institut de Neurociències, Universitat Autònoma de Barcelona, Bellaterra, Spain. Unitat Mixta UAB-VHIR, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. [García-Lareu B] Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Institut de Neurociències, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Bosch A] Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Institut de Neurociències, Universitat Autònoma de Barcelona, Bellaterra, Spain. Unitat Mixta UAB-VHIR, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain |
dc.identifier.pmid | 34630277 |
dc.identifier.wos | 000703767700001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |